This site is intended for health professionals only

Generic donepezil launched across Europe

teaser

Actavis Group, the international generic pharmaceuticals company, today announced the launch of donepezil in some of Europe’s biggest markets, immediately after the patents expired. 

 

The conventional tablets were launched in Germany, France, Italy, Spain, the UK, Denmark, Sweden and Austria this week.

 

Donepezil tablets were developed by Actavis R&D and manufactured by Actavis in Malta.

 

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Actavis is also bringing donepezil oro-dispersible tablets to market following patent expiry in the UK and Sweden.

 

Actavis has already launched Donepezil in a number of patent-free markets.

 

Donepezil is indicated for the treatment of mild to moderately severe Alzheimer’s disease. Donepezil Actavis is the generic equivalent of the brand product Aricept® from Pfizer.

 

The Brand product had sales in the EU of approximately EUR 475.6mln for the 12 months ending September 2011, according to IMS Health.

Actavis






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x